Alzheimer's disease (AD) is a devastating cause of memory loss and cognitive decline, for which no curative treatment is available.

Hemophilia A, a rare genetic disorder marked by a deficiency of clotting factor VIII, leads to prolonged bleeding and joint damage. Enhanced treatment options, like extended half-life clotting factors ...

The Hemophilia B market is growing rapidly due to advancements in gene therapy and diagnostics. This rare genetic disorder, caused by F9 gene mutations, primarily affects males. Revolutionary ...

Liver fibrosis is a growing global concern, driven by chronic conditions like hepatitis, obesity, and alcohol use. This progressive liver disease, marked by scar tissue buildup, can advance to ...

Emcure Pharma and Novo Nordisk India also announced a strategic partnership to launch Poviztra, semaglutide injection 2.4 mg, in India. “The collaboration will strengthen the distribution and ...

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

Novo Nordisk A/S faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy. Learn more ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

Novo Nordisk said on Monday it would lower the U.S. price of its injectable Wegovy obesity drug and pledged to go "all in" on ...

Novo Holdings A/S, a vehicle for the Novo Nordisk Foundation, is set to exit its remaining position in medical technology ...

Novo Nordisk's new chair Lars Sorensen plans to add pharma expertise and address governance concerns after a major board overhaul backed by the company's foundation.